You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 7,989,596

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,989,596

Title:	Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
Abstract:	The binding specificity of a monoclonal antibody is altered by exposing the monoclonal antibody to an oxidizing agent or an electric potential.
Inventor(s):	McIntyre; John A. (Indianapolis, IN)
Assignee:	Redox-Reactive Reagents LLC (Beech Grove, IN)
Application Number:	11/857,608
Patent Claims:	1. A method comprising: providing a solution comprising a monoclonal antibody, the monoclonal antibody having a binding specificity toward a specific first antigen, exposing the composition to an oxidizing agent or an electric potential sufficient to effect an alteration of the binding specificity of the monoclonal antibody, and screening the monoclonal antibody after the composition has been exposed to the oxidizing agent or electric potential to determine whether the monoclonal antibody has a binding affinity for other antigens other than the first antigen, wherein the monoclonal antibody is a therapeutic agent or a candidate therapeutic agent wherein the screening is carried out to assess whether the monoclonal antibody has autoantibody activity under oxidative conditions. 2. The method of claim 1, wherein the oxidizing agent is hemin. 3. The method of claim 1, wherein exposing of the composition to an electric potential is carried out by submersing electrodes connected to a positive and negative terminal of a battery or electric power source into the solution comprising the monoclonal antibody for a predetermined period of time. 4. The method of claim 1, wherein the solution comprising the monoclonal antibody includes the commercial manufacturers' buffers, TRIS buffer, phosphate buffered saline or culture media. 5. A method of claim 1, further comprising recovering the monoclonal antibody having the altered binding specificity from the solution.

Details for Patent 7,989,596

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246	07/20/1983	⤷ Try a Trial	2040-01-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.